Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.11
PMC's Cash to Debt is ranked lower than
52% of the 484 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.84 vs. PMC: 0.11 )
PMC' s 10-Year Cash to Debt Range
Min: 0.04   Max: No Debt
Current: 0.11

Equity to Asset 0.51
PMC's Equity to Asset is ranked higher than
73% of the 481 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.46 vs. PMC: 0.51 )
PMC' s 10-Year Equity to Asset Range
Min: 0.46   Max: 0.88
Current: 0.51

0.46
0.88
F-Score: 5
Z-Score: 3.72
M-Score: -3.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 3.17
PMC's Operating margin (%) is ranked higher than
71% of the 479 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.77 vs. PMC: 3.17 )
PMC' s 10-Year Operating margin (%) Range
Min: -2.49   Max: 6.57
Current: 3.17

-2.49
6.57
Net-margin (%) 1.08
PMC's Net-margin (%) is ranked higher than
63% of the 479 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.36 vs. PMC: 1.08 )
PMC' s 10-Year Net-margin (%) Range
Min: -1.98   Max: 4.02
Current: 1.08

-1.98
4.02
ROE (%) 4.09
PMC's ROE (%) is ranked higher than
60% of the 471 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.86 vs. PMC: 4.09 )
PMC' s 10-Year ROE (%) Range
Min: -7.79   Max: 27.19
Current: 4.09

-7.79
27.19
ROA (%) 2.10
PMC's ROA (%) is ranked higher than
61% of the 478 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.39 vs. PMC: 2.10 )
PMC' s 10-Year ROA (%) Range
Min: -3.54   Max: 19
Current: 2.1

-3.54
19
ROC (Joel Greenblatt) (%) 17.98
PMC's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 478 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.26 vs. PMC: 17.98 )
PMC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -10.31   Max: 21.88
Current: 17.98

-10.31
21.88
Revenue Growth (%) -1.60
PMC's Revenue Growth (%) is ranked higher than
60% of the 329 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.40 vs. PMC: -1.60 )
PMC' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 11.7
Current: -1.6

0
11.7
EBITDA Growth (%) 12.60
PMC's EBITDA Growth (%) is ranked higher than
87% of the 298 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.00 vs. PMC: 12.60 )
PMC' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 17.3
Current: 12.6

0
17.3
EPS Growth (%) -0.50
PMC's EPS Growth (%) is ranked higher than
73% of the 297 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.40 vs. PMC: -0.50 )
PMC' s 10-Year EPS Growth (%) Range
Min: 0   Max: 66.9
Current: -0.5

0
66.9
» PMC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

PMC Guru Trades in Q2 2013

HOTCHKIS & WILEY 1,199,595 sh (+52.95%)
Joel Greenblatt 178,975 sh (+12.06%)
Steven Romick -320,700 sh (unchged)
Chuck Royce 142,500 sh (unchged)
Steven Cohen Sold Out
David Dreman 329,844 sh (-15.42%)
Paul Tudor Jones 40,900 sh (-16.19%)
Jim Simons 194,600 sh (-34.74%)
» More
Q3 2013

PMC Guru Trades in Q3 2013

Joel Greenblatt 215,492 sh (+20.4%)
HOTCHKIS & WILEY 1,282,495 sh (+6.91%)
Steven Romick -320,700 sh (unchged)
David Dreman Sold Out
Paul Tudor Jones 40,200 sh (-1.71%)
Chuck Royce 42,500 sh (-70.18%)
Jim Simons 46,300 sh (-76.21%)
» More
Q4 2013

PMC Guru Trades in Q4 2013

Joel Greenblatt 454,285 sh (+110.81%)
Jim Simons 62,000 sh (+33.91%)
Steven Romick -320,700 sh (unchged)
Chuck Royce 42,500 sh (unchged)
HOTCHKIS & WILEY Sold Out
Paul Tudor Jones 23,213 sh (-42.26%)
» More
Q1 2014

PMC Guru Trades in Q1 2014

Steven Romick -320,700 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PMC

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 Add 110.81%0.12%$13.46 - $22.58 $ 2748%454285
David Dreman 2013-09-30 Sold Out 0.12%$11.86 - $15.4 $ 27100%0
Joel Greenblatt 2013-09-30 Add 20.4%0.02%$11.86 - $15.4 $ 27100%215492
David Dreman 2013-03-31 New Buy0.14%$13.81 - $15.26 $ 2785%389972
Joel Greenblatt 2013-03-31 Add 44.74%0.03%$13.81 - $15.26 $ 2785%159710
Joel Greenblatt 2012-09-30 New Buy0.09%$9.97 - $13.3 $ 27127%104549
Jean-Marie Eveillard 2012-03-31 Sold Out 0.03%$12.06 - $15.39 $ 27121%0
Jean-Marie Eveillard 2011-12-31 Reduce -31.17%0.02%$11.91 - $16.4 $ 2780%513371
Jean-Marie Eveillard 2011-09-30 New Buy0.05%$10.69 - $14.73 $ 27101%745898
John Keeley 2011-09-30 Sold Out 0.0046%$10.69 - $14.73 $ 27101%0
Joel Greenblatt 2011-03-31 Sold Out $10.71 - $12.89 $ 27126%0
John Keeley 2011-03-31 New Buy$10.71 - $12.89 $ 27126%22000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 43.40
PMC's P/E(ttm) is ranked lower than
59% of the 432 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.70 vs. PMC: 43.40 )
PMC' s 10-Year P/E(ttm) Range
Min: 6.37   Max: 113.63
Current: 43.4

6.37
113.63
P/B 1.70
PMC's P/B is ranked higher than
63% of the 471 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.70 vs. PMC: 1.70 )
PMC' s 10-Year P/B Range
Min: 0.57   Max: 2.38
Current: 1.7

0.57
2.38
P/S 0.50
PMC's P/S is ranked higher than
58% of the 496 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.49 vs. PMC: 0.50 )
PMC' s 10-Year P/S Range
Min: 0.12   Max: 0.5
Current: 0.5

0.12
0.5
PFCF 6.40
PMC's PFCF is ranked higher than
96% of the 294 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.92 vs. PMC: 6.40 )
PMC' s 10-Year PFCF Range
Min: 3.24   Max: 42.17
Current: 6.4

3.24
42.17
EV-to-EBIT 19.20
PMC's EV-to-EBIT is ranked lower than
51% of the 456 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.48 vs. PMC: 19.20 )
PMC' s 10-Year EV-to-EBIT Range
Min: 7   Max: 34.4
Current: 19.2

7
34.4
PEG 39.60
PMC's PEG is ranked lower than
62% of the 240 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.47 vs. PMC: 39.60 )
PMC' s 10-Year PEG Range
Min: 0.72   Max: 40.6
Current: 39.6

0.72
40.6
Shiller P/E 35.50
PMC's Shiller P/E is ranked lower than
54% of the 240 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.16 vs. PMC: 35.50 )
PMC' s 10-Year Shiller P/E Range
Min: 16.41   Max: 36.37
Current: 35.5

16.41
36.37

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 18.60
PMC's Price/Tangible Book is ranked lower than
79% of the 402 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.10 vs. PMC: 18.60 )
PMC' s 10-Year Price/Tangible Book Range
Min: 3.47   Max: 14.43
Current: 18.6

3.47
14.43
Price/DCF (Projected) 0.80
PMC's Price/DCF (Projected) is ranked higher than
87% of the 235 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.30 vs. PMC: 0.80 )
PMC' s 10-Year Price/DCF (Projected) Range
Min: 0.53   Max: 0.65
Current: 0.8

0.53
0.65
Price/Median PS Value 1.90
PMC's Price/Median PS Value is ranked lower than
67% of the 451 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.10 vs. PMC: 1.90 )
PMC' s 10-Year Price/Median PS Value Range
Min: 0.75   Max: 1.47
Current: 1.9

0.75
1.47
Price/Peter Lynch Fair Value 8.90
PMC's Price/Peter Lynch Fair Value is ranked lower than
72% of the 138 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.36 vs. PMC: 8.90 )
PMC' s 10-Year Price/Peter Lynch Fair Value Range
Min: 6.91   Max: 6.91
Current: 8.9

Price/Graham Number 6.00
PMC's Price/Graham Number is ranked lower than
74% of the 368 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.45 vs. PMC: 6.00 )
PMC' s 10-Year Price/Graham Number Range
Min: 1.33   Max: 4.64
Current: 6

1.33
4.64
Earnings Yield (Greenblatt) 5.20
PMC's Earnings Yield (Greenblatt) is ranked higher than
53% of the 467 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.40 vs. PMC: 5.20 )
PMC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.9   Max: 14.3
Current: 5.2

2.9
14.3
Forward Rate of Return (Yacktman) 11.37
PMC's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 289 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.91 vs. PMC: 11.37 )
PMC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 8.2   Max: 33.7
Current: 11.37

8.2
33.7

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:SHDMF, APNHF, GNC, JCOUF, CCKRY » details
PharMerica Corporation, a Delaware Corporation was formed on October 23, 2006. It is an institutional pharmacy services company that services healthcare facilities and provides management pharmacy services to hospitals. The Company operates institutional pharmacies and 12 specialty infusion pharmacies in 45 states. It also provides pharmacy management services to 89 hospitals in the United States. Its customers comprise of institutional healthcare providers, such as skilled nursing facilities, nursing centers, assisted living facilities, hospitals, individuals receiving in-home care and other long-term alternative care settings. The Company's main business is to provide pharmacy products and services to residents and patients in skilled nursing facilities, nursing centers, assisted living facilities, hospitals, and other long-term alternative care settings. It purchases, repackages and dispenses prescription and non-prescription pharmaceuticals in accordance with physician orders and delivers such medication to healthcare facilities for administration to individual patients and residents. The Company provides 24-hour, seven-day per week on-call pharmacist services for emergency dispensing, delivery, and/or consultation with the facility's staff or the resident's attending physician.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide